Role of hematological indices in predicting preeclampsia/gestational diabetes and their severity

Pregnancy is a time of profound biological transformation, where the mother's body reorganizes itself to support a growing life. Among the many systems that adapt, the blood undergoes significant changes. The volume of blood increases to carry more oxygen and nutrients, which naturally dilutes the concentration of red blood cells, a normal state known as physiological anemia. At the same time, the immune system shifts its activity, preparing the body for the stress of birth while protecting the fetus. These adjustments are usually smooth and predictable, but when they go awry, they can signal serious complications. Two of the most common and dangerous complications are preeclampsia, a condition marked by high blood pressure and organ stress, and gestational diabetes, a form of high blood sugar that develops during pregnancy. Both conditions are rooted in inflammation and vascular problems, yet doctors often struggle to identify them early enough to prevent harm to the mother and baby.

Researchers have long known that a simple blood test, called a complete blood count, can reveal the health of the immune system and the blood's ability to carry oxygen. This test counts the different types of cells floating in the blood, such as white blood cells that fight infection, red blood cells that carry oxygen, and platelets that help blood clot. From these counts, scientists can also calculate ratios that show how different cell types relate to one another, offering a window into the body's inflammatory state. While previous studies have looked at these numbers at single moments in time, they have missed the story of how these numbers change as pregnancy progresses. Understanding the timeline of these changes is crucial because it could reveal early warning signs before a woman even feels sick.

A team of researchers in Pune, India, set out to map this timeline with unprecedented detail. They followed a large group of pregnant women from the very beginning of their pregnancies through to delivery, collecting blood samples at four distinct stages: early in the first trimester, in the middle of the second trimester, late in the second trimester, and finally at the moment of birth. They also collected blood from the umbilical cord to see how the baby's blood compared to the mother's. The study focused on three groups: women who remained healthy, women who developed preeclampsia, and women who developed gestational diabetes. By tracking the same women over time, the researchers could see exactly when and how their blood profiles began to diverge from the normal path.

The study revealed that the blood of women who would later develop these conditions showed distinct patterns very early on, often before the diseases were clinically diagnosed. In the first trimester, women who went on to develop either preeclampsia or gestational diabetes already had higher total counts of white blood cells compared to healthy pregnant women. This suggests that the body's inflammatory response is triggered much earlier than previously thought. As the pregnancy progressed, the differences became more specific. Women with preeclampsia showed elevated white blood cell counts again in the second trimester, while women with gestational diabetes showed a different pattern, with higher levels of a specific type of white blood cell called lymphocytes appearing later in the pregnancy.

One of the most consistent findings was the behavior of monocytes, a type of white blood cell that acts as a first responder to inflammation. In both groups of women with complications, the number of monocytes circulating in the blood was significantly lower than in healthy women at every stage of pregnancy. This drop was so consistent that it appeared to be a hallmark of both conditions. Because the number of lymphocytes remained relatively stable or even increased in some cases, the ratio of lymphocytes to monocytes became much higher in the women with complications. This specific ratio, which reflects the balance between different immune cells, emerged as a powerful indicator. The researchers found that measuring this ratio, along with the total white blood cell count, could help predict the development of these conditions with reasonable accuracy, particularly when the blood was drawn between 18 and 22 weeks of pregnancy.

The study also looked at the blood of the newborns to understand how these maternal conditions affected the fetus. In the cord blood of babies born to mothers with preeclampsia, the total number of white blood cells was lower than in healthy babies, suggesting that the placental dysfunction associated with the disease may have impaired the baby's ability to produce or mobilize these immune cells. However, the babies' blood did show higher levels of lymphocytes, hinting that the fetal immune system might be shifting its strategy in response to the stressful environment. In both groups of complicated pregnancies, the babies also had lower levels of monocytes and lower inflammatory ratios, mirroring the changes seen in their mothers. This parallel suggests that the inflammatory environment created by the mother's condition directly influences the developing immune system of the fetus.

When the researchers tested how well these blood markers could predict the diseases, they found that combining the data with other factors like the mother's age, body mass index, and the stage of pregnancy improved the accuracy significantly. For preeclampsia, the combination of the lymphocyte-to-monocyte ratio and the total white blood cell count at 18 to 22 weeks showed a strong ability to distinguish between healthy pregnancies and those at risk. Similarly, for gestational diabetes, these same markers provided a clear signal of risk during the same time window. The findings suggest that a routine blood test, which is already standard care in prenatal clinics, could be analyzed in a new way to flag high-risk pregnancies much earlier than current methods allow.

This research does not claim to have solved the mystery of preeclampsia or gestational diabetes, nor does it suggest that these blood markers are the only factors involved. Instead, it offers a clearer picture of the biological journey these conditions take. By showing that the immune system begins to shift months before symptoms appear, the study points toward a future where doctors might be able to intervene sooner, potentially preventing the severe outcomes that these conditions can cause. The work highlights that the story of pregnancy health is written in the blood long before the diagnosis is made, and reading that story early could save lives.